Results are in for an open-label phase 2 clinical trial of interferon gamma (IFN-γ) treatment for Friedreich’s ataxia (FRDA) sponsored by Children’s Hospital of Philadelphia along with collaborators at the Friedreich’s Ataxia Research Alliance and Vidara Therapeutics Research Ltd. David Lynch, MD, PhD, served as the principal investigator. The…
News
Recent Posts
- Limiting iron absorption in gut may help extend lifespan in Friedreich’s ataxia
- Making peace with the changes FA brings, even as I hope for FA to change
- Study identifies promising therapeutic target for Friedreich’s ataxia
- Recovering from a fractured bone takes an emotional toll
- Early-onset FA tied to greater relationship challenges in later stages